The Lirilumab Biosimilar Anti-KIR2DL2 Antibody is a cutting-edge research tool designed for studies involving the KIR2DL2 receptor, a key player in immune cell regulation. This monoclonal antibody, produced using advanced biosimilar technology, is highly specific for human KIR2DL2 and has been rigorously validated for use in various research applications, including flow cytometry and immunohistochemistry.KIR2DL2, also known as killer cell immunoglobulin-like receptor, is a critical component of the immune system that helps regulate the activity of natural killer cells and cytotoxic T cells. Dysregulation of KIR2DL2 signaling has been implicated in a variety of diseases, including cancer, infectious diseases, and autoimmune disorders.
By targeting KIR2DL2, researchers can gain valuable insights into the mechanisms of immune response and potentially identify new therapeutic targets for the treatment of these conditions.The Lirilumab Biosimilar Anti-KIR2DL2 Antibody enables precise detection and analysis of KIR2DL2 expression in various cell types, making it an invaluable tool for studies in immunology, oncology, and infectious disease research. With its high specificity and sensitivity, this antibody opens up new possibilities for uncovering the role of KIR2DL2 in health and disease, paving the way for the development of novel therapies and diagnostic tools.
Product Name:
Lirilumab (Anti-KIR2DL2) Biosimilar Antibody
Size:
100 ug
Product SKU:
HDBS0121
Target:
KIR2DL2
Host Species:
Homo sapiens
Reactivity:
Human
Recommended Dilution:
Flow Cyt 1:100
Antibody Type:
Monoclonal
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
BMS-986015, IPH2102
Description:
Anti-KIR2DL2(lirilumab biosimilar) mAb
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
Flow Cyt
Antibody Isotype:
IgG4
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
